| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Rare Diseases |
Recent Updates
Recently added Catalysts
Disc Medicine, Inc.$76.59
-3.34 (-4.23%)
B 60Pipeline Score Fair Value Biotech · Clinical
Market Cap
2.55 B
EPS
-6.62
P/E Ratio
-
Value Trade
23.27 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
45.90 M
Operating CF
-62.24 M
Total Assets
750.21 M
Total Liabilities
61.78 M
Equity
688.43 M
D/E Ratio
12,345
-3.5 %
Week
-3.84 %
1 Month
6.4 %
3 Month
-26.04 %
6 Month
-38.36 %
5 Year
-34.81 %
All Time
Cash Data
Cash Position
730.16 M
Monthly Burn
20.75 M
Runway
33.2 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
324.98 K
52 Week Range
40.00 - 99.50
% held by Insiders
28.1 %
% held by Institutions
90.75 %
Enterprise Value
1.85 B
Total Shares
37.73 M
Short %
20.39 %
Float Shares
31.20 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Disc Medicine, Inc.
272Total events
19Upcoming
66Tier-1 (high impact)
2019 – 2027Coverage
Upcoming catalysts 19
Event history 253
Jun 15, 2026
Jun 13, 2026
▲Poster PresentationbitopertinPresentation
Poster presentation of updated HELIOS data at EHA 2026
erythropoietic protoporphyriasource ↗
Jun 12, 2026
▲Oral PresentationDISC-0974Presentation
Oral presentation of updated RALLY-MF data at EHA 2026
myelofibrosis with anemiasource ↗
Jun 9, 2026
▲Type A MeetingbitopertinFDA Meeting
Completed Type A meeting with FDA to discuss CRL for bitopertin NDA
erythropoietic protoporphyriasource ↗
Jun 2, 2026
◆Oral PresentationDISC-0974Presentation
Oral presentation of RALLY-MF Phase 2 data at ASCO 2026
anemia of myelofibrosissource ↗
Jun 1, 2026
▲Trial InitiationbitopertinTrial
Phase 3 APOLLO trial ongoing
erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP)source ↗
Jun 2026
◆Oral PresentationDISC-0974Presentation
Updated Phase 2 data of DISC-0974 in MF anemia to be presented at ASCO
anemia of myelofibrosis (MF)source ↗
May 21, 2026
◆AbstractDISC-0974Presentation
Abstract publication on ASCO conference website
anemia of myelofibrosissource ↗
May 5, 2026
▲Enrollment CompletebitopertinTrial
Completed enrollment of Phase 3 APOLLO study of bitopertin in EPP
erythropoietic protoporphyria (EPP)source ↗
May 2026
◆PDUFA DatebitopertinRegulatory Filing
PDUFA date expected (if Priority Review granted, ~6 months after filing acceptance)
erythropoietic protoporphyria (EPP)source ↗
Q2 2026
◆Type A MeetingbitopertinFDA Meeting
Type A meeting with FDA to review approach for CRL resubmission
erythropoietic protoporphyria (EPP)source ↗
Drug Pipeline Intelligence
B60
Pipeline Score $2.3B
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored0.9x
rNPV / MCap Top 88%
Small Cap (rank 110 of 911)
Percentile RankDisc Medicine, Inc. holds a solid B-grade pipeline (60/100), with $3.5B risk-adjusted pipeline value, led by DISC-0974 in Chronic Kidney Diseases (Phase 1), across $138B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DISC-0974 Small molecule | Inflammatory Bowel Disease (IBD) | Phase 2 | NCT07368972 | 31% | $3.1B | RECRUITING | 21 | AVERAGE | C (59) | Mar 1, 2027 | LOW_RISK | LOW Jul 6, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
DISC-0974 Fast Track | myelofibrosis | Phase 2 | 2026-06-12 | meaningful, durable overall anemia responses across all patient subgroups; >75% reduction from baseline in hepcidin; corresponding increases in serum iron Read More | Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting Read More | |
DISC-0974 Fast Track | myelofibrosis | Phase 2 | 2026-06-12 | meaningful, durable overall anemia responses across all patient subgroups; >75% reduction from baseline in hepcidin; corresponding increases in serum iron Read More | Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting Read More | |
DISC-0974 Fast Track | myelofibrosis | Phase 2 | 2026-06-12 | meaningful, durable overall anemia responses across all patient subgroups; >75% reduction from baseline in hepcidin; corresponding increases in serum iron Read More | Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IRON
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IRON Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IRONDisc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims for shareholders of Disc Medicine, Inc. (NASDAQ: IRON) due to allegations of misleading business information. A Complete Response Letter from the FDA rejected the company's new drug application, causing a 22% drop in the stock price. Investors who purchased securities may be entitled to compensation through a class action lawsuit, with no upfront costs. The firm encourages investors to consult experienced legal counsel for such matters.
Read more →IRONDisc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting
Disc Medicine presented positive clinical updates at the EHA Annual Meeting, showcasing significant results from the RALLY-MF trial for DISC-0974 in myelofibrosis patients and the HELIOS trial for bitopertin in erythropoietic protoporphyria. The data indicate durable anemia responses and improved light tolerance, respectively. The company anticipates further developments in its clinical programs, including upcoming discussions with the FDA.
Read more →IRONDisc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria
Disc Medicine has completed a Type A meeting with the FDA regarding the Complete Response Letter for bitopertin, a treatment for erythropoietic protoporphyria. The FDA indicated that the ongoing Phase 3 APOLLO study could support a response to the CRL and potential traditional approval. Results from the APOLLO study are anticipated in Q4 2026, with a CRL response submission planned by the end of 2026.
Read more →IRON▼ -5.5%on this news
Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Disc Medicine presented updated positive data from the RALLY-MF Phase 2 trial at the ASCO Annual Meeting. The trial demonstrated significant anemia responses in patients with myelofibrosis, showing improvements regardless of transfusion status or JAK inhibitor therapy. The investigational drug DISC-0974 was well-tolerated, with promising results in hemoglobin increases and transfusion independence.
Read more →IRONDisc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
Disc Medicine has announced an expanded access program for bitopertin, aimed at patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). This program allows eligible patients to access the treatment prior to regulatory approval. Bitopertin is currently being evaluated in the Phase 3 APOLLO clinical trial, with results expected in Q4 2026 and a potential FDA decision by mid-2027.
Read more →IRONDisc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
Read more →IRONDisc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine to Participate in Upcoming Investor Conferences
Read more →IRONDisc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update
Disc Medicine reported its first quarter 2026 financial results, highlighting the completion of enrollment in the Phase 3 APOLLO study of bitopertin for erythropoietic protoporphyria, with topline data expected in Q4 2026. The company also announced updates on its other clinical programs, including DISC-0974 and DISC-3405, with significant financial resources to support ongoing operations. Despite a net loss increase, the company remains optimistic about its pipeline and future milestones.
Read more →IRONDisc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting
Disc Medicine announced an oral presentation of data from the RALLY-MF Phase 2 trial of DISC-0974, targeting anemia in myelofibrosis. The presentation will occur at the ASCO Annual Meeting from May 29 to June 2, 2026. Initial results indicate unprecedented anemia response rates, showcasing the drug's potential in treating this difficult condition.
Read more →IRONDisc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria
Disc Medicine has completed enrollment for the Phase 3 APOLLO trial of bitopertin, now involving 183 participants due to high demand. The trial aims to evaluate bitopertin's effectiveness in treating erythropoietic protoporphyria (EPP). Results are expected in Q4 2026, with a potential FDA decision by mid-2027.
Read more →IRONDisc Medicine, Inc. Investigated by the Portnoy Law Firm
Disc Medicine, Inc. is under investigation by the Portnoy Law Firm for possible securities fraud following a significant drop in stock price. The decline of 21.91% occurred after the FDA issued a Complete Response Letter regarding their drug bitopertin, indicating regulatory issues with clinical trial data. Ongoing concerns about the drug's safety and efficacy have further weakened investor confidence. The law firm aims to assist investors in pursuing claims to recover losses incurred due to these developments.
Read more →IRONDisc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Disc Medicine, Inc. reported its financial results for Q4 and full year 2025, highlighting progress in its clinical programs. The company expressed confidence in the bitopertin program and the Phase 3 APOLLO study, aiming for FDA approval. Additionally, promising data from DISC-0974 and upcoming results from DISC-3405 were noted, indicating a strong pipeline.
Read more →IRON▲ +17.2%on this news
Bitopertin Regulatory Update February 2026 Disclaimer and FLS This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, b
Disc has received a Complete Response Letter from the FDA for bitopertin, particularly related to the adequacy of protoporphyrin IX as a biomarker. The FDA has requested further evidence from the ongoing APOLLO study to establish clinical efficacy. While Disc is determined to gather necessary data and respond to the agency's concerns, the response indicates significant hurdles ahead for regulatory approval. The completion of the APOLLO study is pivotal, with results expected in late 2026.
Read more →IRON▼ -21.9%on this newsshared move
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP • FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and
Disc Medicine, Inc. announced the receipt of a Complete Response Letter from the FDA regarding its New Drug Application for bitopertin, intended for treating erythropoietic protoporphyria. While the FDA acknowledged supportive evidence from earlier trials, it highlighted the need for results from the ongoing Phase 3 APOLLO study before making a final decision. Enrollment for the APOLLO trial has been completed ahead of schedule, with topline data expected in Q4 2026.
Read more →IRONDisc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
Disc Medicine, Inc. has outlined its strategic priorities and achievements for 2026, highlighting significant progress in its clinical pipeline. The company received CNPV designation for bitopertin and submitted an NDA for accelerated FDA review. Positive Phase 2 data from DISC-0974 and the advancement of DISC-3405 into proof-of-concept studies were also noted. The company aims for a successful US launch of bitopertin while continuing to expand its clinical studies.
Read more →IRONDisc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer
Read more →IRONDisc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference
Disc Medicine, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. CEO John Quisel will lead the presentation, which will be available via live webcast. The company specializes in developing treatments for serious hematologic diseases, emphasizing innovative therapeutic candidates targeting red blood cell biology.
Read more →IRONDisc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
Disc Medicine presented positive initial data from its RALLY-MF Phase 2 trial for DISC-0974 at the ASH Annual Meeting. The trial showed significant reductions in hepcidin and increased iron levels, leading to improved anemia outcomes in patients with myelofibrosis. The company aims to address the unmet need for anemia treatment in this patient population.
Read more →IRONDisclaimer and FLS This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied state
Disc has made significant progress in the development of its investigational drug bitopertin, with the New Drug Application (NDA) accepted by the FDA. The company aims to launch bitopertin by the end of January 2026, contingent on approval, and is advancing its commercialization plans. Updated clinical data indicate positive outcomes in patients with anemia of myelofibrosis, with improvements in hemoglobin levels and reduced transfusion burdens. The company is also exploring additional applications for its product candidates and engaging in ongoing clinical trials.
Read more →IRONDisc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update
Disc Medicine, Inc. reported its third quarter 2025 financial results, highlighting significant progress in its drug development pipeline. The company successfully submitted a New Drug Application for bitopertin and received a Critical New Product Validation. With a solid financial foundation, Disc anticipates further advancements in its clinical trials and preparations for potential product launches.
Read more →IRONDisc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
Disc Medicine announced the presentation of initial data from the RALLY-MF Phase 2 trial of DISC-0974 at the upcoming ASH Annual Meeting. The trial focuses on patients with myelofibrosis and anemia. The company will also present ongoing trials for DISC-3405 in polycythemia vera and sickle cell disease. A management call is scheduled to discuss the findings.
Read more →IRONDisc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
Disc Medicine, Inc. has announced the pricing of an upsized public offering of common stock and pre-funded warrants, aiming to raise approximately $225 million. The offering includes 2,619,049 shares of common stock priced at $84.00 each. Proceeds will be used for the commercialization of bitopertin and further development of product candidates. The offering is set to close on October 22, 2025.
Read more →IRONDisc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Disc Medicine, Inc. has announced a proposed public offering of $220 million in common stock and pre-funded warrants. The funds will support the commercialization of bitopertin for erythropoietic protoporphyria and other product candidates. The offering is subject to market conditions, and there is no guarantee on its completion or terms.
Read more →IRONDisc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
Disc Medicine, Inc. has provided an update on its hematology portfolio, focusing on the development of three key indications: EPP, MF, and PV. The company is preparing for potential commercialization of bitopertin following FDA's CNPV grant and is advancing its iron homeostasis programs, with data from ongoing trials expected soon. Future trials are planned for anemia of inflammatory bowel disease and sickle cell disease.
Read more →IRON▲ +21%on this newsshared move
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
Disc Medicine, Inc. announced it will present data from its Phase 1b trial of DISC-0974 at the 2025 ASN Kidney Week. The study focuses on patients with non-dialysis-dependent chronic kidney disease and anemia, assessing safety, tolerability, and pharmacokinetics. The presentation will include updates from all cohorts and is scheduled for November 8, 2025.
Read more →IRON▲ +21%on this newsshared move
Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)
Disc Medicine, Inc. announced the receipt of a Commissioner’s National Priority Voucher from the FDA for bitopertin, aimed at treating erythropoietic protoporphyria (EPP). This voucher is part of a program designed to expedite drug development aligned with national health priorities. Bitopertin, currently under review, has shown promise in clinical trials and has received special designations from the FDA.
Read more →IRONDisc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)
Disc Medicine has submitted a New Drug Application (NDA) to the FDA for bitopertin, aimed at treating erythropoietic protoporphyria (EPP) in patients aged 12 and older. The submission leverages data from Phase 2 studies demonstrating significant reductions in protoporphyrin IX levels and improvements in patient quality of life. The company has requested Priority Review to expedite the FDA's evaluation process.
Read more →IRONDisc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic
Disc Medicine, Inc. (NASDAQ:IRON) has provided a comprehensive update regarding its hematology portfolio and upcoming business objectives. The company is focused on accelerating the development of its key treatments, including bitopertin, for which they have submitted a New Drug Application for FDA consideration. In addition, initial data for its iron homeostasis programs is expected by the end of the year, with further trials planned for 2026. Disc Medicine is positioning itself to meet potential patient needs effectively if regulatory approvals are granted.
Read more →IRONDisc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update • Company on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approval pathway in
Disc Medicine reported its financial results for Q2 2025, noting progress on multiple drug development programs, particularly the NDA submission for bitopertin in erythropoietic protoporphyria (EPP) anticipated in October 2025. The company showcased promising clinical data from various studies during the European Hematology Association (EHA) Annual Congress and maintains a strong financial position with $650.0 million in cash. However, the company reported an increased net loss driven by higher research and development expenses.
Read more →IRONDisc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025
Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025
Read more →IRONDisc Medicine Appoints Nadim Ahmed to its Board of Directors
Disc Medicine Appoints Nadim Ahmed to its Board of Directors
Read more →IRONDisc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress
Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress
Read more →IRONDisc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
Read more →IRONDisc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Read more →IRONDisc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update • Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 • Initiated
Disc Medicine reported its first quarter financial results for 2025, highlighting a strong cash position and significant advancements in their clinical programs. The company is on track to submit a New Drug Application (NDA) for bitopertin for erythropoietic protoporphyria by the second half of 2025 and has initiated the APOLLO trial for this therapy. Financially, Disc has $695 million in cash, which is expected to support operations through 2028. However, the firm also reported a net loss of $34.1 million during the first quarter, reflecting ongoing financial pressures.
Read more →IRONDisc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF)
Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF)
Read more →IRONDisc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Targeting NDA submission for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 through accelerated approva
Disc Medicine reported its fourth quarter and full year 2024 financial results, highlighting significant milestones such as positive Phase 2 results for bitopertin and ongoing preparations for the APOLLO trial. The company aims to submit a New Drug Application (NDA) in the second half of 2025, potentially leading to accelerated approval for treatments related to erythropoietic protoporphyria (EPP). Despite these advancements, Disc reported a net loss and faces challenges in maintaining operational funding and managing the timelines of ongoing clinical trials.
Read more →IRONDisc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
Read more →IRONDisc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants WATERTOWN, Mass. (
Disc Medicine, Inc. has announced a proposed public offering of $200 million in common stock and pre-funded warrants. The company aims to utilize the proceeds for research and clinical development related to its hematologic disease treatments, particularly bitopertin. The offering is subject to market conditions, and underwriters have a 30-day option to purchase additional shares. Potential risks include uncertainty in the timing and actual completion of the offering.
Read more →IRONDisc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission Pursuing accelerated approval for bitopertin in EPP with protoporphyrin
Disc Medicine, Inc. has received positive feedback from the FDA following a Type C meeting regarding their investigational drug bitopertin for treating Erythropoietic Protoporphyria (EPP). The company plans to submit a New Drug Application (NDA) in the second half of 2025, aiming for accelerated approval based on the surrogate endpoint of protoporphyrin IX (PPIX) reduction. The upcoming APOLLO post-marketing confirmatory trial is scheduled to begin in mid-2025, with sites planned in the US, Canada, Europe, and Australia. Bitopertin has the potential to be the first disease-modifying therapy for EPP patients, which currently lack effective treatments.
Read more →IRONDisc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
Read more →IRONDisc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)
Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)
Read more →IRON▼ -5.3%on this news
Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025 • In Q1 2025, the Company will discuss the plans for NDA submission under a potential ac
Disc Medicine announced significant advancements in its hematology portfolio, highlighting plans for NDA submission for bitopertin in EPP following positive discussions with the FDA. Initial data from phase 1b studies of DISC-0974 and DISC-3405 are expected in late 2025. The company successfully completed phase 2 studies, leading to robust clinical data that support its future development programs and initiatives. Disc also strengthened its financial position through a substantial equity offering.
Read more →IRONDisc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
Read more →IRONDisc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting
Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting
Read more →IRONDisc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment
Disc Medicine, Inc. (NASDAQ:IRON) announced its financial results for the third quarter of 2024, highlighting significant progress in its therapeutic pipeline. The company successfully completed a Phase 2 meeting with the FDA regarding bitopertin, which shows potential for accelerated approval in treating erythropoietic protoporphyria (EPP). Additionally, Disc reported a significant net loss of $26.6 million for the quarter, up from the previous year's $14.1 million, despite a strong financial position bolstered by debt financing. The results indicate both promising advancements and financial challenges as the company moves forward.
Read more →IRONDisc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. • Facility significantly increases future financial and operational flexibility • Up to $200M available, with $3
Disc Medicine, Inc. has successfully obtained a non-dilutive $200 million debt financing facility from Hercules Capital, Inc., which will significantly enhance the company's financial and operational flexibility. This funding will allow Disc to support its clinical development across its portfolio, including a potential confirmatory study of bitopertin in erythropoietic protoporphyria. The financing consists of up to four tranches and is designed to enable strategic flexibility in future capital formation as the company prepares for key milestones through 2026.
Read more →IRON▲ +11.2%on this newsshared move
Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
Read more →IRON▲ +23.6%on this news· ran to +37% by day 1shared move
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval • Alignment with the FDA across all proposed s
Disc Medicine announced a positive outcome from its end-of-Phase 2 meeting with the FDA regarding its investigational treatment, bitopertin, for Erythropoietic Protoporphyria (EPP). The FDA aligned with the proposed primary endpoint for clinical development and acknowledged the potential for accelerated approval based on existing data. The company plans to conduct the APOLLO trial, aimed at further validating bitopertin's efficacy, starting mid-2025. Additionally, the FDA agreed to consider using PPIX reduction as a surrogate endpoint to support a new drug application under the Accelerated Approval Program.
Read more →IRON▲ +5.2%on this news· ran to +45% by day 3shared move
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
Read more →IRONDisc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week
Disc Medicine, Inc. presented promising data from a Phase 1b trial of DISC-0974 at the ASN Kidney Week 2024. The trial focused on patients with non-dialysis-dependent chronic kidney disease and anemia, showcasing the drug's ability to significantly reduce hepcidin and improve hemoglobin levels after a single dose. Results showed a durable reduction in hepcidin and a meaningful increase in transferrin saturation, indicating a strong potential for further development in treating anemia linked to various chronic diseases. The safety profile was considered acceptable, with most adverse events rated Grade 1 or 2.
Read more →IRON▼ -7.7%on this newsshared move
Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer
Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer
Read more →IRONDisc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
Read more →IRONDisc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer
Read more →IRONDisc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update Presented positive data for all three programs at the European Hematology Association (EHA) 2024 Congress; demonstrated potential e
Disc Medicine, Inc. (NASDAQ:IRON) announced its financial results for Q2 2024, reporting a net loss of $26.4 million amid rising operating expenses. The company highlighted positive data from the European Hematology Association 2024 Congress, noting that their clinical programs are progressing well. As part of recent milestones, Disc secured financing from notable investors, which is expected to support their upcoming clinical trials. The company expressed optimism about its portfolio's therapeutic potential as it moves forward with new regulatory interactions and milestones.
Read more →IRON▲ +18.2%on this news
Disc Medicine Announces Underwritten Offering of Common Stock WATERTOWN, Mass. (
Disc Medicine, Inc. has announced an underwritten offering of 4,944,000 shares of common stock priced at $36.00 per share, aiming to raise approximately $178 million. The offering will close on June 17, 2024, contingent on customary closing conditions. Funds will be allocated towards research, clinical development, and general corporate purposes, with participation from various institutional investors. The announcement highlights the company's continued commitment to developing treatments for serious hematologic diseases.
Read more →IRON▲ +18.2%on this news
Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress Updated analyses of data from AURORA and BEACON studies further demonstrate clinical activity of b
Disc Medicine, Inc. announced promising clinical data at the EHA 2024 Congress, highlighting the efficacy of its investigational drugs. The updated analyses from the AURORA study showed significant clinical activity of bitopertin in erythropoietic protoporphyria, showcasing improvements in light tolerance and quality of life. Moreover, findings from the Phase 1b trial of DISC-0974 indicated sustainable increases in hemoglobin levels among patients with myelofibrosis anemia. Additionally, initial data from the Phase 1 trial of DISC-3405 suggested its potential as an iron restriction agent.
Read more →IRONDisc Medicine to Participate in the Jefferies Global Healthcare Conference
Disc Medicine to Participate in the Jefferies Global Healthcare Conference
Read more →IRONDisc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
Read more →IRONDisc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
Read more →IRONDisc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update Presented top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), in Ap
Disc Medicine, Inc. (NASDAQ:IRON) provided its first quarter 2024 financial results along with business updates, emphasizing the progress of its clinical candidate, bitopertin, in treating erythropoietic porphyrias (EPP). The latest topline data showcased significant efficacy for bitopertin in reducing toxic PPIX levels, leading to improved quality of life for patients. The company anticipates sharing further data from ongoing studies in June and aims to engage in regulatory discussions by the second half of the year. Financially, the company reported a net loss of approximately $26.9 million for the quarter.
Read more →IRON▼ -45.1%on this news
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
Disc Medicine, Inc. reported topline data from the Phase 2 AURORA study of bitopertin in patients with Erythropoietic Protoporphyria (EPP). The results indicate significant reductions in the toxic metabolite PPIX and improvements in phototoxic reactions among patients treated with bitopertin. However, one secondary endpoint related to sunlight exposure did not reach statistical significance. The company plans to analyze additional data and work with experts to establish proper endpoints for future studies.
Read more →IRON▼ -7.5%on this news
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP),
Disc Medicine, Inc. has reported its fourth quarter and full year 2023 financial results, highlighting a significant year of progress. The company demonstrated positive clinical trial results for its therapies, including bitopertin and DISC-0974. Additionally, it advanced DISC-3405 into clinical studies and improved its financial standing. However, the company also reported a substantial net loss, raising concerns about operating expenses and financial sustainability moving forward.
Read more →IRONDisc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
Read more →IRONDisc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer Pamela Stephenson is an accomplished industry executive with over 25 years of global commercia
Disc Medicine, a clinical-stage biopharmaceutical company, has appointed Pamela Stephenson as Chief Commercial Officer. With over 25 years of experience in global commercial leadership, Stephenson will oversee Disc's commercialization strategy. Her background includes successful launches in rare disease therapies, and her role is pivotal as Disc moves into late-stage development. This expansion in leadership is viewed positively as the company aims to advance its treatment offerings for patients with serious hematologic diseases.
Read more →IRONDisc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Read more →IRONDisc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
Read more →IRONDisc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer Jean Franchi is an industry veter
Disc Medicine, Inc. has appointed Jean Franchi as the new Chief Financial Officer and promoted Jonathan Yu to Chief Operating Officer. Franchi brings over 30 years of finance leadership experience and will focus on capital formation and financial strategy as the company anticipates significant clinical data read-outs this year. The leadership changes signify a strengthening of Disc's management team as they prepare for late-stage development and potential commercialization of their hematologic treatments.
Read more →IRONDisc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Read more →IRONDisc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board
Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board
Read more →IRONDisc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65 th American Society of Hematology (ASH) Annual Meeting Substantial, dose-dependent r
Disc Medicine, Inc. presented promising initial data from its ongoing Phase 1b/2 trial of DISC-0974 for patients with myelofibrosis (MF) and anemia at the 65th ASH Annual Meeting. The results indicate a significant reduction in serum hepcidin levels and improvements in serum iron and hemoglobin. DISC-0974 targets the hemojuvelin co-receptor to alleviate anemia driven by elevated hepcidin in MF patients. This marks a significant advancement for the company, as it has shown notable hematologic activity early in treatment across different patient types.
Read more →IRONDisc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65 th American Society of Hematology (ASH) Annual Meeting Updated data from BEACON continued to demonstrate signifi
Disc Medicine, Inc. presented updated results from the Phase 2 BEACON study of bitopertin for patients with erythropoietic protoporphyria at the 65th ASH Annual Meeting. The data confirmed earlier positive findings, highlighting significant reductions in PPIX levels and substantial improvements in sunlight tolerance and patient quality of life. With promising results from both the BEACON study and initial efficacy data from another study, Disc is poised for future growth and advancements in their hematologic disease portfolio.
Read more →IRONDisc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin
Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin
Read more →IRONDisc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update Completed enrollment of BEACON and AURORA trials of bitopertin in erythropoietic protoporphyria (EPP); BEACON expanded to include ad
Disc Medicine, Inc. (NASDAQ:IRON) reported its third quarter 2023 financial results and highlighted the completion of enrollment in the BEACON and AURORA clinical trials for its investigational treatment, bitopertin. The company anticipates presenting interim data at the ASH 2023 meeting. Disc is focused on developing novel therapies for serious hematologic diseases, including additional programs like DISC-0974 and DISC-3405, aimed at addressing anemia and iron homeostasis. Financial results reflect a significant increase in research and development expenses, leading to a net loss compared to the previous year.
Read more →IRONDisc Medicine Announces Multiple Presentations Across Portfolio at the 65 th American Society of Hematology Annual Meeting and Key Program Updates Completion of enrollment for phase 2 BEACON and AURORA studies of bitoper
Disc Medicine, Inc. has announced key updates and multiple presentations for its portfolio at the upcoming 65th American Society of Hematology Annual Meeting, scheduled for December 9-12, 2023, in San Diego, CA. Notably, the company has completed full enrollment for its BEACON and AURORA phase 2 studies of bitopertin in patients with erythropoietic protoporphyria (EPP). Additionally, interim data from the BEACON trial and preliminary results from DISC-0974 studies will be presented, highlighting the company's commitment to treating serious hematologic diseases.
Read more →IRONDisc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce
Disc Medicine, Inc. announced the planned departure of Chief Financial Officer Joanne Bryce, who has been with the company since its inception. She will remain to oversee her current responsibilities until a successor is found. Bryce has played a crucial role in establishing Disc’s operations and financial position, thanked by the company’s CEO for her contributions. The company is positioned for growth and late-stage development despite the leadership change.
Read more →IRONDisc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers
Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers
Read more →IRONDisc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera
Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera
Read more →IRONDisc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update Presented positive initial safety and efficacy data from BEACON trial at the European Hematology Association (EHA) Congress in June
Disc Medicine, Inc. reported its second quarter 2023 financial results and provided an update on its business operations. The company highlighted positive initial data from the BEACON trial presented at the European Hematology Association Congress, which supports the potential of bitopertin as a treatment for erythropoietic porphyrias (EPP). Despite a successful public offering that secures funding for future developments, the company also reported a significant net loss and higher operating expenses when compared to the same quarter last year. Disc plans to advance bitopertin into late-stage development and looks forward to reporting further results by the end of the year.
Read more →IRONDisc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)
Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)
Read more →IRONDisc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Read more →IRONDisc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Read more →IRON▲ +6.9%on this newsshared move
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants WATERTOWN, Mass. (GLOBE NEWSWIRE)
Disc Medicine, a clinical-stage biopharmaceutical company, has launched a proposed public offering of $100 million in common stock and pre-funded warrants. The proceeds from this offering are intended to support the research and clinical development of its product candidates. The offering is dependent on market conditions and includes an underwriter option for an additional $15 million of shares. Investors are cautioned about the risks related to the offering, including stock price fluctuations and uncertainties in market conditions.
Read more →IRON▲ +15.8%on this newsshared move
Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress Consistent and dose-dependent reduct
Disc Medicine has presented positive preliminary data from its Phase 2 BEACON trial of bitopertin for treating patients with erythropoietic protoporphyria (EPP) at the EHA 2023 Congress. The results indicated consistent decreases in PPIX levels and significant improvements in patients' sunlight tolerance and quality of life. The trial, which involves both EPP and X-linked protoporphyria patients, continues to gather data, with further results expected by the end of the year. Disc Medicine plans to leverage this momentum for additional clinical developments across its portfolio.
Read more →IRON▲ +12%on this news· ran to +25% by day 3
Disc Medicine to Participate in the Jefferies Healthcare Conference
Disc Medicine to Participate in the Jefferies Healthcare Conference
Read more →IRONDisc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update Two ongoing Phase 2 studies of bitopertin in EPP; initial safety and efficacy data from open-label BEACON trial to be presented at t
Disc Medicine, Inc. reported their Q1 2023 financial results and highlighted their development progress in novel treatments for hematologic diseases. The company has multiple ongoing Phase 2 studies of bitopertin, targeting conditions such as erythropoietic porphyrias and anemia of inflammation. With an anticipated presentation of initial data from the BEACON trial, Disc is committed to advancing its clinical pipeline. However, they reported a net loss of $22.8 million, raising concerns about the financial sustainability of their operations moving forward.
Read more →IRONDisc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress
Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress
Read more →IRON▲ +11.6%on this news
Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference
Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference
Read more →IRONDisc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)
Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)
Read more →IRONDisc Medicine Reports Full Year 2022 Financial Results and Provides Business Update Completed reverse merger with Gemini Therapeutics, debuting on Nasdaq as IRON and ending 2022 with approximately $194.6 million in cash
Disc Medicine, Inc. (NASDAQ:IRON) reported its full year financial results for 2022, highlighting significant transformations following its reverse merger with Gemini Therapeutics. The company ended the year with about $194.6 million in cash, positioning itself for future growth. Notably, it has progressed its lead candidates, bitopertin and DISC-0974, into patient studies and ramped up its pipeline with new initiatives. Despite a net loss recorded for the year, Disc remains focused on establishing a strong foothold in the hematology market.
Read more →IRONDisc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)
Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)
Read more →IRONDisc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
Read more →IRONDisc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs WATERTOWN, Mass. (
Disc Medicine, Inc. announced a successful $62.5 million financing round led by Bain Capital Life Sciences to further develop its novel hematology programs. The funding includes a securities purchase agreement allowing for the sale of common stock and pre-funded warrants. This strategic investment is expected to enhance Disc Medicine's financial strength and support upcoming clinical trials aiming at important therapeutic advancements in hematologic diseases. The deal is anticipated to close by February 15, 2023, pending standard closing conditions.
Read more →IRONDisc Medicine to Participate in SVB Securities Global Biopharma Conference
Disc Medicine to Participate in SVB Securities Global Biopharma Conference
Read more →IRONDisc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis Disc will obtain exclusive rights to MWTX-003 and other novel anti
Disc Medicine has entered into an exclusive licensing agreement with Mabwell Therapeutics to obtain rights to a portfolio of monoclonal antibodies targeting TMPRSS6, including the phase 1-ready candidate MWTX-003. This agreement allows Disc to develop and commercialize these antibodies in regions outside of China and Southeast Asia. MWTX-003 aims to modulate iron homeostasis and has potential implications for various hematologic disorders. Disc plans to initiate a phase 1 trial for MWTX-003 in healthy volunteers in the latter half of 2023.
Read more →IRONDisc Medicine Announces Completion of Merger with Gemini Therapeutics The combined company will operate as Disc Medicine and will trade on the Nasdaq Global Market under the ticker symbol "IRON" Approximately $175 millio
Disc Medicine Announces Completion of Merger with Gemini Therapeutics WATERTOWN, Mass. (December 29, 2022) - Disc Medicine, Inc. ("Disc"), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients su
Read more →IRONDisc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria WATERTOWN, Mass. (
Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic WATERTOWN, Mass. (December 27, 2022) Disc Medicine, Inc. ( Disc ), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of no
Read more →IRONDisc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting WATERTOWN, Mass. (
Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting WATERTOWN, Mass. (December 13, 2022) Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commerc
Read more →IRONDisc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting
Disc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting
Read more →IRONDisc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP) AURORA study designed to evaluate bitopertin as a potential disease-modifying treatment for adults
Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP) WATERTOWN, Mass. (October 31, 2022) Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization o
Read more →IRONCONFIDENTIAL Conference Call Transcript Gemini Therapeutics and Disc Medicine Merger Agreement Announcement
Conference Call Transcript Gemini Therapeutics and Disc Medicine Merger Agreement Announcement August 10, 2022 / 08:00 AM ET CORPORATE PARTICIPANTS Georges Gemayal Gemini Therapeutics, Chair of the Board and Interim CEO John Quisel President and CEO of Disc Medicine Welcome
Read more →IRONGemini Therapeutics and Disc Medicine Announce Merger Agreement Merger to create NASDAQ-listed, clinical-stage biopharmaceutical company focused on advancing Disc Medicine s portfolio of hematology programs Combined comp
Gemini Therapeutics and Disc Medicine Announce Merger Agreement WAYLAND, Mass. and WATERTOWN, Mass. (August 10, 2022) Gemini Therapeutics, Inc. (Nasdaq: GMTX) ( Gemini ) and Disc Medicine, Inc. ( Disc ), a privately-held, clinical-stage biopharmaceutical company focused on the
Read more →IRONDisc Medicine Initiates BEACON, a Phase 2 Clinical Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP)
Disc Medicine Initiates BEACON, a Phase 2 Clinical Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP)
Read more →IRONDisc Medicine Initiates Phase 1b/2 Clinical Study of DISC-0974 in Myelofibrosis Patients with Severe Anemia
Disc Medicine Initiates Phase 1b/2 Clinical Study of DISC-0974 in Myelofibrosis Patients with Severe Anemia
Read more →IRONDisc Medicine Presents Positive Results from Phase 1 Clinical Study of DISC-0974 in Healthy Volunteers at the 2022 EHA Annual Congress
Disc Medicine Presents Positive Results from Phase 1 Clinical Study of DISC-0974 in Healthy Volunteers at the 2022 EHA Annual Congress
Read more →IRONDisc Medicine Announces Presentation of Clinical Data from First-in-Human Phase 1 Study of DISC-0974 at European Hematology Association (EHA) 2022 Congress
Disc Medicine Announces Presentation of Clinical Data from First-in-Human Phase 1 Study of DISC-0974 at European Hematology Association (EHA) 2022 Congress
Read more →IRONGemini Therapeutics Reports 2021 Financial Results Remote-First-Company/Mass.
Gemini Therapeutics Reports 2021 Financial Results Remote-First-Company/Mass. March 10, 2022 Gemini Therapeutics, Inc. (Nasdaq: GMTX) today reported financial results for the year ended December 31, 2021. As previously announced this year, Gemini Therapeutics has initiated a p
Read more →IRONGemini Therapeutics Provides Corporate Update Remote-First-Company/Mass.
Gemini Therapeutics Provides Corporate Update Remote-First-Company/Mass. February 28, 2022 Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), toda
Read more →IRONGemini Therapeutics Provides GEM103 Program Update
Gemini Therapeutics Provides GEM103 Program Update CAMBRIDGE, Mass. January 10, 2022 Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today anno
Read more →IRONDisc Medicine Appoints Jay T. Backstrom, M.D., M.P.H., to its Board of Directors and Rahul Khara, Pharm.D., J.D., as General Counsel
Disc Medicine Appoints Jay T. Backstrom, M.D., M.P.H., to its Board of Directors and Rahul Khara, Pharm.D., J.D., as General Counsel
Read more →IRONGemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update GEM103 updated safety information presented during AAO including no increased risk for CNV observed to date in ongoing ReGAtta
Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update GEM103 updated safety information presented during AAO including no increased risk for CNV observed to date in ongoing ReGAtta Phase 2a study Expect to provide six-month update from
Read more →IRONGemini Therapeutics Announces Poster Presentation at AAO 2021
Gemini Therapeutics Announces Poster Presentation at AAO 2021 CAMBRIDGE, Mass. November 12, 2021 Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD)
Read more →IRONDisc Medicine Announces Oral Presentation on Bitopertin at the 63rd American Society of Hematology Annual Meeting
Disc Medicine Announces Oral Presentation on Bitopertin at the 63rd American Society of Hematology Annual Meeting
Read more →IRONGemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy CAMBRIDGE, Mass. October 5, 2 021 Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical
Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy CAMBRIDGE, Mass. October 5, 2021 Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative tre
Read more →IRONDisc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases
Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases
Read more →IRONDisc Medicine Appoints Will Savage, MD, PhD as Chief Medical Officer and Jonathan Yu as Chief Business Officer and Expands Scientific Leadership with Key Hires to Advance Clinical-Stage Pipeline
Disc Medicine Appoints Will Savage, MD, PhD as Chief Medical Officer and Jonathan Yu as Chief Business Officer and Expands Scientific Leadership with Key Hires to Advance Clinical-Stage Pipeline
Read more →IRONGemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update Initial data from ongoing Phase 2a study in geographic atrophy demonstrated ability of GEM103 to durably regulate complement
Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update CAMBRIDGE, Mass. August 12, 2021 Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-re
Read more →IRONDisc Medicine Initiates Phase 1 Clinical Study of DISC-0974, a First-In-Class Inhibitor of Hemojuvelin (HJV) in Development for the Treatment of Anemia of Inflammation
Disc Medicine Initiates Phase 1 Clinical Study of DISC-0974, a First-In-Class Inhibitor of Hemojuvelin (HJV) in Development for the Treatment of Anemia of Inflammation
Read more →IRONGemini Therapeutics Announces Initial Data from its Ongoing Phase 2a Study of GEM103 in Patients with Geographic Atrophy Secondary to Dry Age-related Macular Degeneration - Biomarker results indicate GEM103 s ability to
Gemini Therapeutics Announces Initial Data from its Ongoing Phase 2a Study of GEM103 in Patients with Geographic Atrophy Secondary to Dry Age-related Macular Degeneration - Biomarker results indicate GEM103 s ability to regulate complement and complement factor H therapeutic a
Read more →IRONDisc Medicine Expands Hematology Pipeline with Worldwide Licensing Agreement for Bitopertin, a First-in-Class Modulator of Heme Synthesis
Disc Medicine Expands Hematology Pipeline with Worldwide Licensing Agreement for Bitopertin, a First-in-Class Modulator of Heme Synthesis
Read more →IRONDisc Medicine to Present at the European Hematology Association (EHA) 2021 Virtual Congress
Disc Medicine to Present at the European Hematology Association (EHA) 2021 Virtual Congress
Read more →IRONDisc Medicine to Present at the Jefferies Virtual Healthcare Conference
Disc Medicine to Present at the Jefferies Virtual Healthcare Conference
Read more →IRONGemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update Fast Track Designation for GEM103 in dry AMD granted January 2021 GEM103 Phase 2a study in geographic atrophy data on track fo
Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update CAMBRIDGE, Mass. May 13, 2021 Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related
Read more →IRONGemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer
Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer CAMBRIDGE, Mass. - April 12, 2021 - Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular de
Read more →IRONGemini Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update - Business combination with FS Development Corp. resulted in new public listing, strengthened management team, and cash position o
Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update Mass. - March 29, 2021 - Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degener
Read more →IRONUNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION The following unaudited pro forma combined balance sheet of Combined Entity as of
PRO FORMA COMBINED FINANCIAL INFORMATION following unaudited pro forma combined balance sheet of Combined Entity as of September 30, 2020 and the unaudited pro forma combined statements of operations of Combined Entity for the year ended December 31, 2019 and nine months ended
Read more →IRONFS Development Corp. Announces Effectiveness of Registration Statement for Proposed Business Combination with Gemini Special Meeting Scheduled for
Development Corp. Announces Effectiveness of Registration Statement for Business Combination with Gemini Meeting Scheduled for February 3, 2021 FRANCISCO, CA, January 19, 2021 - FS Development Corp., a Delaware corporation (the "Company") (Nasdaq: FSDC), announced today that
Read more →IRONDisc Medicine Appoints William White to its Board of Directors
Disc Medicine Appoints William White to its Board of Directors
Read more →IRONDisc Medicine to Present at the Virtual 62nd American Society of Hematology Annual Meeting
Disc Medicine to Present at the Virtual 62nd American Society of Hematology Annual Meeting
Read more →IRONDisc Medicine to Present at the Piper Sandler 32nd Annual Healthcare Conference
Disc Medicine to Present at the Piper Sandler 32nd Annual Healthcare Conference
Read more →IRONGemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular Degeneration - Leading institutional investors commit $95 million
Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular Degeneration Combined company is expected to be listed on Nasdaq - Business combination is expected to be completed by Janu
Read more →IRONDisc Medicine to Present at Citi's 15th Annual BioPharma Virtual Conference
Disc Medicine to Present at Citi's 15th Annual BioPharma Virtual Conference
Read more →IRONFS DEVELOPMENT CORP. Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of
Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of August 14, 2020 F-3 Notes to Financial Statement F-4 of Independent Registered Public Accounting Firm To the Stockholders and the Board of Directors of FS Development Corp. Opinion on the Finan
Read more →IRONFS Development Corp., Sponsored by Foresite Capital, Announces Pricing of Upsized $105 Million Initial Public Offering San Francisco, CA
Development Corp., Sponsored by Foresite Capital, Announces Pricing of Upsized $105 Million Initial Public Offering CA - August 12, 2020 - FS Development Corp. (the "Company") announced today that it priced its initial public offering of 10,500,000 shares of Class A common stoc
Read more →IRONDisc Medicine Expands Leadership Team with Industry Veterans to Advance Hepcidin Modulating Therapies Toward the Clinic
Disc Medicine Expands Leadership Team with Industry Veterans to Advance Hepcidin Modulating Therapies Toward the Clinic
Read more →IRONJohn Quisel, JD, PhD Joins Disc Medicine as President and Chief Executive Officer
John Quisel, JD, PhD Joins Disc Medicine as President and Chief Executive Officer
Read more →IRONDisc Medicine Expands Pipeline Focused on Hepcidin Pathway
Disc Medicine Expands Pipeline Focused on Hepcidin Pathway
Read more →IRONDisc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production
Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production
Read more →Competitive Position
How IRON ranks across every disease it competes inCompetitive Position is a premium feature
See how IRON ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial